Sisomicin

Sisomicin 구조식 이미지
카스 번호:
32385-11-8
상품명:
Sisomicin
동의어(영문):
SISOMYCIN;Siseptin;Sch 13475;Sisomicin;Rickamicin;Sisomicin base;Antibiotic 6640;Sisomicin (8CI);Sisomicin USP/EP/BP;Sisomicin impurity 1
CBNumber:
CB9875243
분자식:
C19H37N5O7
포뮬러 무게:
447.53
MOL 파일:
32385-11-8.mol

Sisomicin 속성

녹는점
80-93°C
끓는 점
556.56°C (rough estimate)
밀도
1.2777 (rough estimate)
굴절률
1.7600 (estimate)
저장 조건
Hygroscopic, -20°C Freezer, Under Inert Atmosphere
용해도
산성 용액(약간 용해됨), DMSO(약간 용해됨), 메탄올(약간 용해됨), 물(약간 용해됨)
물리적 상태
고체
물리적 상태
단단한 모양
산도 계수 (pKa)
13.29±0.70(Predicted)
색상
연한 노란색에서 노란색까지
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
그림문자(GHS): Exclamation Mark (GHS07)Health Hazard (GHS08)
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H312 피부와 접촉하면 유해함 급성 독성 물질 - 경피 구분 4 경고 P280,P302+P352, P312, P322, P363,P501
H332 흡입하면 유해함 급성 독성 물질 흡입 구분 4 경고 P261, P271, P304+P340, P312
H360 태아 또는 생식능력에 손상을 일으킬 수 있음 생식독성 물질 구분 1A, 1B 위험
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P271 옥외 또는 환기가 잘 되는 곳에서만 취급하시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P302+P352 피부에 묻으면 다량의 물로 씻으시오.
P304+P340 흡입하면 신선한 공기가 있는 곳으로 옮기고 호흡하기 쉬운 자세로 안정을 취하시오.
P312 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.
P322 특정 조치(라벨의 … 참조)
P363 다시 사용전 오염된 의류는 세척하시오.
P501 ...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
3 0

Sisomicin C화학적 특성, 용도, 생산

개요

Sisomicin was found in the culture broth of Micromonospora inyoensis by Schering-Plough Co. in 1970, following the discovery of gentamicin by the same research group. The structure and activity of sisomicin are very similar to those of gentamicin C1a, the major component of the gentamicin complex. Sisomicin shows stronger bacterial activity and lower renal and ototoxicity than gentamicin C1a .

화학적 성질

Off-White Solid

용도

Sisomicin is an Antibacterial. Gentamicin-like aminoglycoside antibiotic; has broad spectrum antibiotic activity.

Antimicrobial activity

A fermentation product of Micromonospora inyoensis. A dehydro derivative of gentamicin C1a, supplied as the sulfate salt.
It is virtually identical to gentamicin in activity and pharmacokinetic behavior. An intramuscular dose of 1–1.5 mg/kg achieves a peak plasma concentration of 1.5–9.0 mg/L after 0.5–1 h. It is widely distributed in body water, but concentrations in CSF are low, even in the presence of inflammation. The plasma half-life is 2.5 h and protein binding is <10%.
It is eliminated almost completely over 24 h in the glomerular filtrate. Excretion decreases proportionately with renal impairment and because of the virtual identity of the behavior of the two compounds, a gentamicin nomogram can be used to adjust dosage. About 40% of the dose is eliminated during a 6-h dialysis period, during which the elimination half-life falls to about 8 h.
Mild and reversible impairment of renal function occurs in about 5% of patients. Nephrotoxicity is more likely to be seen in those with pre-existing renal disease or treated concurrently with other potentially nephrotoxic drugs. Ototoxicity mainly affecting vestibular function has been found in about 1% of patients. Neuromuscular blockade and other effects common to aminoglycosides including rashes, paresthesiae, eosinophilia and abnormal liver function tests have been described.
Its uses are identical to those of gentamicin, which it closely resembles. It is of limited availability.

일반 설명

This aminoglycoside antibiotic is produced by Micromonospora inyoensis. Sisomicin is very similar to gentamicin in its antimicrobial spectrum and all other properties. It is as active as gentamicin against all Enterobacteriaceae . Against Pseudomonas aeruginosa, sisomicin is more active than gentamicin, but not as active as tobramycin. There is almost complete cross-resistance between gentamicin and sisomicin with most Gram-negative bacilli. The reason for this is that sisomicin, like gentamicin, is affected by at least eight of the plasmid-coded modifying enzymes, which can be produced by Gram-negative bacilli). On the other hand, sisomicin is active against some organisms which resist gentamicin by nonenzymatic mechanisms. Sisomicin does not offer significant advantages over gentamicin. It has had limited clinical trials, and has been available commercially in Europe as a sulfate, but not in the USA, UK, and Australia. The drug dosage of sisomicin (3–6 mg/kg/day), its methods of administration, and pharmacokinetics, are similar to those of gentamicin. The toxicity of these two drugs is also probably about the same. Results of treatment of conditions, such as urinary tract infections or Gramnegative bacillary septicemias, have, in general, been similar to what would be expected from an identical gentamicin regimen.

Sisomicin 준비 용품 및 원자재

원자재

준비 용품


Sisomicin 공급 업체

글로벌( 112)공급 업체
공급자 전화 이메일 국가 제품 수 이점
J & K SCIENTIFIC LTD. 18210857532 18210857532
jkinfo@jkchemical.com China 96815 76
Chemsky(shanghai)International Co.,Ltd. 021-50135380
shchemsky@sina.com China 32273 50
Beijing HuaMeiHuLiBiological Chemical 010-56205725
waley188@sohu.com China 12323 58
Guangzhou Isun Pharmaceutical Co., Ltd 020-39119399 18927568969
isunpharm@qq.com China 4773 55
Nanjing Sunlida Biological Technology Co., Ltd. 025-57798810 18652991625
sales@sunlidabio.com China 3223 55
Shanghai TaoSu Biochemical Technology Co., Ltd. 021-33632979
info@tsbiochem.com China 8039 58
Shanghai GAOXIANG Chemical Co., Ltd. 021-57816257 18930243658
fecpo@139.com China 295 55
Cato Research Chemicals Inc. 020-81960175
min.he@cato-chem.com China 1949 55
Quality Control Solutions Ltd. 0755-66853366 13670046396
orders@qcsrm.com China 18188 56
Shanghai Macklin Biochemical Co.,Ltd. 15221275939 15221275939
shenlinxing@macklin.cn China 15775 55

Sisomicin 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved